Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Total Valuation
Jasper Therapeutics has a market cap or net worth of $82.47M. The enterprise value is -$27.16M.
Market Cap$82.47M
Enterprise Value-$27.16M
Share Statistics
Jasper Therapeutics has 15,022,122 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,022,122
Owned by Insiders2.37%
Owned by Institutions40.92%
Financial Efficiency
Jasper Therapeutics’s return on equity (ROE) is -1.16 and return on invested capital (ROIC) is -113.57%.
Return on Equity (ROE)-1.16
Return on Assets (ROA)-0.89
Return on Invested Capital (ROIC)-113.57%
Return on Capital Employed (ROCE)-1.18
Revenue Per Employee0.00
Profits Per Employee-1.11M
Employee Count64
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Jasper Therapeutics is -4.38. Jasper Therapeutics’s PEG ratio is 0.00.
PE Ratio-4.38
PS Ratio0.00
PB Ratio0.00
Price to Fair Value5.06
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.00
Income Statement
In the last 12 months, Jasper Therapeutics had revenue of 0.00 and earned -71.27M in profits. Earnings per share was -4.89.
Revenue0.00
Gross Profit0.00
Operating Income-76.24M
Pretax Income-72.76M
Net Income-71.27M
EBITDA-71.39M
Earnings Per Share (EPS)-4.89
Cash Flow
In the last 12 months, operating cash flow was -69.71M and capital expenditures -527.00K, giving a free cash flow of -70.23M billion.
Operating Cash Flow-69.71M
Free Cash Flow-70.23M
Free Cash Flow per Share-4.68
Dividends & Yields
Jasper Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.52
52-Week Price Change-76.27%
50-Day Moving Average5.13
200-Day Moving Average11.75
Relative Strength Index (RSI)52.24
Average Volume (3m)233.33K
Important Dates
Jasper Therapeutics upcoming earnings date is Aug 8, 2025, After Close (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date―
Financial Position
Jasper Therapeutics as a current ratio of 4.98, with Debt / Equity ratio of 0.00%
Current Ratio4.98
Quick Ratio4.98
Debt to Market Cap<0.01
Net Debt to EBITDA0.98
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Jasper Therapeutics has paid -1.49M in taxes.
Income Tax-1.49M
Effective Tax Rate0.02
Enterprise Valuation
Jasper Therapeutics EV to EBITDA ratio is -3.39, with an EV/FCF ratio of -3.83.
EV to Sales0.00
EV to EBITDA-3.39
EV to Free Cash Flow-3.83
EV to Operating Cash Flow-3.87
Balance Sheet
Jasper Therapeutics has $48.80M in cash and marketable securities with $2.59M in debt, giving a net cash position of -$46.21M billion.
Cash & Marketable Securities$48.80M
Total Debt$2.59M
Net Cash-$46.21M
Net Cash Per Share-$3.08
Tangible Book Value Per Share$4.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Jasper Therapeutics is $47.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$47.57
Price Target Upside766.48% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast21.40%